Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
DRD3 Antagonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023
DRD3 Antagonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Dopamine receptors include D1-like (D1, D5) and D2-like (D2, D3, D4) subtypes. The D3 receptor is primarily located in the brain, especially in regions like the limbic system, nucleus accumbent, and islands of Calleja, playing a role in reward, emotion, and motor function. DRD3 antagonists are a class of drugs that target the dopamine D3 receptors in the brain. These receptors are part of the dopamine system, crucial in regulating mood, behavior, and cognition. The mechanism of action involves blocking the activation of D3 receptors, leading to altered dopamine signaling. DRD3 antagonists have been investigated as potential treatments for neuropsychiatric disorders, including schizophrenia, bipolar disorder, and major depressive disorder. By modulating dopamine neurotransmission, these antagonists aim to alleviate symptoms associated with these conditions, such as psychosis, mood disturbances, and cognitive impairments. However, the development and clinical use of DRD3 antagonists are still in the early stages, and more research is needed to fully understand their therapeutic potential and determine their effectiveness and safety in treating these complex neuropsychiatric disorders. As the dopamine system and its role in mental health disorders advance, DRD3 antagonists hold promise as a targeted therapeutic approach, offering hope for improving the lives of those affected by these challenging conditions. Extensive research is being conducted to find new and novel molecules to prevent and cure these diseases. The development and launch of newer products by the market players will significantly enhance the revenue of the DRD3 Antagonists market over the forecast years.
Several of these inhibitors are in the market, while many are in ongoing clinical trials. 18 companies in their pipelines have 19 products in various stages of clinical trials. 2 products are in Phase 4, 3 products are in Phase 3, and 2 products are in Phase 2 of the clinical trials.
Approved molecules
Drugs in Pipeline
Clinical Activity and Developments of DRD3 Antagonists
As of July 2023, 19 products for 97 diseases are in 94 clinical trials. For instance,
|
Molecule name |
Number of studies |
|
Abilify Maintena (aripiprazole depot formulation) |
47 |
|
Abilify MyCite (aripiprazole tablets embedded with sensor) |
8 |
|
dordaviprone (ONC201) |
35 |
|
Barhemsys (intravenous amisulpride) |
14 |
|
TAK-906 |
6 |
DRD3 antagonists have been studied as potential therapeutic agents for various neuropsychiatric disorders. One of the primary indications where they find the most use is in schizophrenia treatment. By targeting the dopamine D3 receptors in the brain, these antagonists aim to modulate dopamine signaling, which may help alleviate the positive and negative symptoms of schizophrenia. Additionally, DRD3 antagonists have shown promise in treating substance use disorders, particularly in managing drug cravings and withdrawal symptoms. The D3 receptors' involvement in the reward pathways makes these antagonists potential candidates for reducing drug-seeking behavior and promoting abstinence. Furthermore, these drugs have been investigated for their potential in managing mood disorders, such as bipolar disorder and major depressive disorder, alcohol-related disorders, Hyperinsulinism, Type 2 Diabetes, Mood disorders, and more. Although still in the early stages of research, DRD3 antagonists hold potential as targeted therapies for these challenging neuropsychiatric conditions, offering hope for improved outcomes and better quality of life for affected individuals.
The global net sales of Abilify Maintena by Lundbeck A/S were $419 million in the financial year 2022, which was 22% more than the sales in 2021while there is a growth of 31% when comparing the sales in 4th quarter of 2022 with that of 2021. According to the WHO 2019 report, globally, 40 million people have experienced bipolar disorder, while 280 million people are living with depression that, includes 23 million children and adolescents. Also, 24 million people globally have schizophrenia. The prevalence and incidence rates of neurological and psychotic disorders differ with the gender, region, and age factors, but these have been increasing globally for many decades, which is an opportunity for the market players globally.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Abilify Maintena (aripiprazole depot formulation) and Abilify MyCite (aripiprazole tablets embedded with sensor) are approved by the FDA.
These are being used in various indications like Schizophrenia, Mood disorders, Type 2 Diabetes, Depression and many more.
Otsuka Pharmaceuticals, Lundbeck A/S, Chimerix Inc, Eagle Pharmaceuticals and Takeda Pharmaceuticals are some of the major market players for DRD3 Antagonists.
Rising incidence of diseases improvement in technologies, development of new treatment lines in the market and changing lifestyles leading to different type of cancers like Neurological and Psychotic disorders are the key opportunities for DRD3 Antagonists in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.